Recce Pharmaceuticals is pleased to announce the acceptance of its China Patent for RECCE® Anti-Infectives, further strengthening its patent portfolio in a key pharmaceutical market valued at US$4.09 billion. The patent covers various aspects of RECCE® 327 and RECCE® 529, validating the anti-infectives' efficacy in treating bacterial and viral infections. This marks the Company's fifth Family 4 patent, with submissions in other strategic markets. CEO James Graham emphasized the significance of this milestone in expanding Recce's reach into the world's second-largest pharmaceutical market. The Company's New Class of Anti-Infectives, designed to combat antibiotic-resistant superbugs, has been recognized for its technical advantages. Investors are encouraged to explore this development and its implications for Recce's growth strategy.